A cross‐section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID‐19) era – a shifting paradigm?
- Resource Type
- Article
- Authors
- Stroman, Luke; Cathcart, Paul; Lamb, Alastair; Challacombe, Ben; Popert, Rick
- Source
- BJU International. Jan2021, Vol. 127 Issue 1, p30-34. 5p.
- Subject
- *COVID-19
*MEDICAL personnel
*COVID-19 pandemic
*ENDORECTAL ultrasonography
*SARS-CoV-2
*SURGICAL gloves
*PROSTATE biopsy
- Language
- ISSN
- 1464-4096
Keywords: Prostate biopsy; #PCSM; #ProstateCancer; #uroonc; #COVID19; #Coronavirus EN Prostate biopsy #PCSM #ProstateCancer #uroonc #COVID19 #Coronavirus 30 34 5 12/29/20 20210101 NES 210101 Abbreviations COVID-19 coronavirus disease 2019 FFP3 filtering facepiece 3 GA general anaesthetic LA local anaesthetic PPE personal protective equipment TP transperineal TR transrectal The prostate cancer diagnostic pathway accounts for >50 000 prostate biopsies each year [1]. The "TRexit" (complete cessation of TRUS prostate biopsies) plan is to move away from TR biopsy and introduce LATP biopsy throughout the UK [5]. A LATP biopsy was the preferred method of prostate biopsy by clinicians during the COVID-19 pandemic. [Extracted from the article]